Systematic review with network meta-analysis: Comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis
Alimentary Pharmacology and Therapeutics | Dec 16, 2017
Bonovas S, et al. - This meta-analysis was performed to comparatively evaluate the efficacy and harm of tofacitinib and biologics (infliximab, adalimumab, golimumab, and vedolizumab) in adult patients with ulcerative colitis (UC) who were not previously exposed to TNF antagonists. For UC, tofacitinib and biologics were found to be efficacious and safe.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
